Free Trial

Xencor (XNCR) Stock Forecast & Price Target

Xencor logo
$24.13 +0.12 (+0.50%)
(As of 12/20/2024 05:17 PM ET)

Xencor - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
9

Based on 9 Wall Street analysts who have issued ratings for Xencor in the last 12 months, the stock has a consensus rating of "Buy." Out of the 9 analysts, 8 have given a buy rating, and 1 has given a strong buy rating for XNCR.

Consensus Price Target

$36.56
51.49% Upside
According to the 9 analysts' twelve-month price targets for Xencor, the average price target is $36.56. The highest price target for XNCR is $50.00, while the lowest price target for XNCR is $28.00. The average price target represents a forecasted upside of 51.49% from the current price of $24.13.
Get the Latest News and Ratings for XNCR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Xencor and its competitors.

Sign Up

XNCR Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
10 Buy rating(s)
Hold
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$36.56$35.75$34.44$41.56
Forecasted Upside51.49% Upside48.34% Upside63.48% Upside98.45% Upside
Consensus Rating
Buy
Buy
Buy
Buy

XNCR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

XNCR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Xencor Stock vs. The Competition

TypeXencorMedical CompaniesS&P 500
Consensus Rating Score
3.11
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside51.49% Upside25,828.55% Upside14.54% Upside
News Sentiment Rating
Neutral News

See Recent XNCR News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/12/2024Wells Fargo & Company
3 of 5 stars
 Initiated CoverageOverweight$37.00+46.48%
12/2/2024Piper Sandler
2 of 5 stars
E. Tenthoff
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$20.00 ➝ $30.00+17.19%
11/8/2024BMO Capital Markets
4 of 5 stars
 Reiterated RatingOutperform ➝ Outperform$32.00 ➝ $34.00+44.37%
11/7/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$27.00 ➝ $28.00+22.97%
11/7/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$38.00+63.58%
9/26/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$31.00 ➝ $34.00+66.83%
6/14/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetStrong-Buy ➝ Strong-Buy$58.00 ➝ $40.00+91.66%
4/16/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$56.00 ➝ $38.00+99.37%
1/22/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$59.00 ➝ $50.00+149.87%
11/8/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$40.00 ➝ $34.00+98.60%
5/19/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$42.00+61.23%
5/15/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Stavropoulos
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
2/24/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$48.00 ➝ $42.00+25.75%
2/24/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$42.00+25.41%
2/23/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Chang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:43 AM ET.


XNCR Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Xencor is $36.56, with a high forecast of $50.00 and a low forecast of $28.00.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XNCR shares.

According to analysts, Xencor's stock has a predicted upside of 51.49% based on their 12-month stock forecasts.

Over the previous 90 days, Xencor's stock had 1 upgrade by analysts.

Xencor has been rated by research analysts at BMO Capital Markets, JPMorgan Chase & Co., Piper Sandler, Royal Bank of Canada, Wedbush, and Wells Fargo & Company in the past 90 days.

Analysts like Xencor more than other "medical" companies. The consensus rating for Xencor is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how XNCR compares to other companies.


This page (NASDAQ:XNCR) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners